US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 9, 2018 (9 years ago)

Tacrolimus USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.

What was recalled

Tacrolimus USP (Monohydrate) for prescription compounding, packaged in a) 1g (NDC 58597-8029-4); b) 5g (NDC 58597-8029-5), RX only, packed by American Pharmaceutical Ingredients, LLC 6650 Highland Road, Waterford, MI 48327

Recalling firm
American Pharmaceutical Ingredients LLC
NDC code
58597-8029-4
Origin
MI, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0523-2018

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Tacrolimus recalls

See all
Class I · High risk Ongoing

Prograf

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0607-73 D-0211-2025
Class I · High risk Ongoing

Astagraf XL

Reason Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Astellas Pharma US Inc. NDC 0469-0647-73 D-0210-2025
Class II · Moderate risk Terminated

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: One 0.5 mg Tacrolimus capsule found in a bottle of 1 mg Tacrolimus capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-526-01 D-0219-2024
Class II · Moderate risk Ongoing

Tacrolimus Capsules

Reason Presence of Foreign Tablets/Capsules: Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules.

Dr. Reddy's Laboratories, Inc. NDC 55111-525-01 D-0330-2023
Class II · Moderate risk Terminated

Tacrolimus 0.03% Oph Solution Tacrolimus 0.1%

Reason Lack of Assurance of Sterility: FDA inspection revealed insanitary conditions at the facility.

Pharmacy Innovations D-0237-2023